Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Observation after surgery for low grade glioma: long-term outcome in the light of the 2016 WHO classification.

Jansen E, Hamisch C, Ruess D, Heiland DH, Goldbrunner R, Ruge MI, Schnell O, Grau SJ.

J Neurooncol. 2019 Oct 16. doi: 10.1007/s11060-019-03316-7. [Epub ahead of print]

PMID:
31621043
2.

Risk Factors for Progression Among Low-Grade Gliomas After Gross Total Resection and Initial Observation in the Molecular Era.

Tom MC, Varra V, Leyrer CM, Park DY, Chao ST, Yu JS, Suh JH, Reddy CA, Balagamwala EH, Broughman JR, Kotagal KA, Vogelbaum MA, Barnett GH, Ahluwalia MS, Peereboom DM, Prayson RA, Stevens GHJ, Murphy ES.

Int J Radiat Oncol Biol Phys. 2019 Aug 1;104(5):1099-1105. doi: 10.1016/j.ijrobp.2019.04.010. Epub 2019 Apr 22.

PMID:
31022510
3.

18F-DOPA uptake does not correlate with IDH mutation status and 1p/19q co-deletion in glioma.

Cicone F, Carideo L, Scaringi C, Arcella A, Giangaspero F, Scopinaro F, Minniti G.

Ann Nucl Med. 2019 Apr;33(4):295-302. doi: 10.1007/s12149-018-01328-3. Epub 2019 Jan 3.

PMID:
30607877
4.

Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.

Leu K, Ott GA, Lai A, Nghiemphu PL, Pope WB, Yong WH, Liau LM, Cloughesy TF, Ellingson BM.

J Neurooncol. 2017 Aug;134(1):177-188. doi: 10.1007/s11060-017-2506-9. Epub 2017 May 25.

5.

Malignant Transformation of Molecularly Classified Adult Low-Grade Glioma.

Tom MC, Park DYJ, Yang K, Leyrer CM, Wei W, Jia X, Varra V, Yu JS, Chao ST, Balagamwala EH, Suh JH, Vogelbaum MA, Barnett GH, Prayson RA, Stevens GHJ, Peereboom DM, Ahluwalia MS, Murphy ES.

Int J Radiat Oncol Biol Phys. 2019 Aug 25. pii: S0360-3016(19)33660-0. doi: 10.1016/j.ijrobp.2019.08.025. [Epub ahead of print]

PMID:
31461674
6.

Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.

Kawaguchi T, Sonoda Y, Shibahara I, Saito R, Kanamori M, Kumabe T, Tominaga T.

J Neurooncol. 2016 Sep;129(3):505-514. doi: 10.1007/s11060-016-2201-2. Epub 2016 Jul 11.

PMID:
27401154
7.

Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.

Akyerli CB, Yüksel Ş, Can Ö, Erson-Omay EZ, Oktay Y, Coşgun E, Ülgen E, Erdemgil Y, Sav A, von Deimling A, Günel M, Yakıcıer MC, Pamir MN, Özduman K.

J Neurosurg. 2018 Apr;128(4):1102-1114. doi: 10.3171/2016.11.JNS16973. Epub 2017 Jun 16.

PMID:
28621624
8.

Surgical management of lower-grade glioma in the spotlight of the 2016 WHO classification system.

Delev D, Heiland DH, Franco P, Reinacher P, Mader I, Staszewski O, Lassmann S, Grau S, Schnell O.

J Neurooncol. 2019 Jan;141(1):223-233. doi: 10.1007/s11060-018-03030-w. Epub 2018 Nov 22.

PMID:
30467813
9.

Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma.

Hu X, Martinez-Ledesma E, Zheng S, Kim H, Barthel F, Jiang T, Hess KR, Verhaak RGW.

Neuro Oncol. 2017 Jun 1;19(6):786-795. doi: 10.1093/neuonc/now285.

10.

Huge heterogeneity in survival in a subset of adult patients with resected, wild-type isocitrate dehydrogenase status, WHO grade II astrocytomas.

Poulen G, Gozé C, Rigau V, Duffau H.

J Neurosurg. 2018 Apr 20:1-10. doi: 10.3171/2017.10.JNS171825. [Epub ahead of print]

PMID:
29676695
11.

IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.

Leeper HE, Caron AA, Decker PA, Jenkins RB, Lachance DH, Giannini C.

Oncotarget. 2015 Oct 6;6(30):30295-305. doi: 10.18632/oncotarget.4497.

12.

Radiological characteristics based on isocitrate dehydrogenase mutations and 1p/19q codeletion in grade II and III gliomas.

Yamauchi T, Ohno M, Matsushita Y, Takahashi M, Miyakita Y, Kitagawa Y, Kondo E, Tsushita N, Satomi K, Yoshida A, Ichimura K, Narita Y.

Brain Tumor Pathol. 2018 Jul;35(3):148-158. doi: 10.1007/s10014-018-0321-4. Epub 2018 Jun 19.

PMID:
29922974
13.

TERT promoter mutations contribute to subset prognostication of lower-grade gliomas.

Chan AK, Yao Y, Zhang Z, Chung NY, Liu JS, Li KK, Shi Z, Chan DT, Poon WS, Zhou L, Ng HK.

Mod Pathol. 2015 Feb;28(2):177-86. doi: 10.1038/modpathol.2014.94. Epub 2014 Aug 1.

14.

To treat or not to treat? A retrospective multicenter assessment of survival in patients with IDH-mutant low-grade glioma based on adjuvant treatment.

Paľa A, Coburger J, Scherer M, Ahmeti H, Roder C, Gessler F, Jungk C, Scheuerle A, Senft C, Tatagiba M, Synowitz M, Wirtz CR, Schmitz B, Unterberg AW.

J Neurosurg. 2019 Jul 19:1-8. doi: 10.3171/2019.4.JNS183395. [Epub ahead of print]

PMID:
31323633
15.

Contemporary assessment of extent of resection in molecularly defined categories of diffuse low-grade glioma: a volumetric analysis.

Kavouridis VK, Boaro A, Dorr J, Cho EY, Iorgulescu JB, Reardon DA, Arnaout O, Smith TR.

J Neurosurg. 2019 Oct 25:1-11. doi: 10.3171/2019.6.JNS19972. [Epub ahead of print]

PMID:
31653812
16.

Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT.

Pekmezci M, Rice T, Molinaro AM, Walsh KM, Decker PA, Hansen H, Sicotte H, Kollmeyer TM, McCoy LS, Sarkar G, Perry A, Giannini C, Tihan T, Berger MS, Wiemels JL, Bracci PM, Eckel-Passow JE, Lachance DH, Clarke J, Taylor JW, Luks T, Wiencke JK, Jenkins RB, Wrensch MR.

Acta Neuropathol. 2017 Jun;133(6):1001-1016. doi: 10.1007/s00401-017-1690-1. Epub 2017 Mar 2.

17.

Management of patients with recurrence of diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.

Nahed BV, Redjal N, Brat DJ, Chi AS, Oh K, Batchelor TT, Ryken TC, Kalkanis SN, Olson JJ.

J Neurooncol. 2015 Dec;125(3):609-30. doi: 10.1007/s11060-015-1910-2. Epub 2015 Nov 3. Review.

PMID:
26530264
18.

Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas.

Sabha N, Knobbe CB, Maganti M, Al Omar S, Bernstein M, Cairns R, Çako B, von Deimling A, Capper D, Mak TW, Kiehl TR, Carvalho P, Garrett E, Perry A, Zadeh G, Guha A, Sidney Croul.

Neuro Oncol. 2014 Jul;16(7):914-23.

19.

Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort.

Tabouret E, Nguyen AT, Dehais C, Carpentier C, Ducray F, Idbaih A, Mokhtari K, Jouvet A, Uro-Coste E, Colin C, Chinot O, Loiseau H, Moyal E, Maurage CA, Polivka M, Lechapt-Zalcman E, Desenclos C, Meyronet D, Delattre JY, Figarella-Branger D; For POLA Network.

Acta Neuropathol. 2016 Oct;132(4):625-34. doi: 10.1007/s00401-016-1611-8. Epub 2016 Aug 29.

PMID:
27573687
20.

Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas.

Yang P, Cai J, Yan W, Zhang W, Wang Y, Chen B, Li G, Li S, Wu C, Yao K, Li W, Peng X, You Y, Chen L, Jiang C, Qiu X, Jiang T; CGGA project.

Neuro Oncol. 2016 Aug;18(8):1099-108. doi: 10.1093/neuonc/now021. Epub 2016 Mar 7.

Supplemental Content

Support Center